Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial


Featuring: David O'Malley, MD, The Ohio State University


Editor’s Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data